Taming the Medical Literature ~ For Genetic Conditions ~ Hand-Curated • Direct to You
LitAlert ~~ GeneLit.com
Somatic Inactivation of Breast Cancer Predisposition Genes in Tumours Associated with Pathogenic Germline Variants.
Lim BWX, Li N, Mahale S, Mcinerny S, Zethoven M, Rowley SM, Huynh J, Wang T, Lee JEA, Friedman M, Devereux L, Scott RJ, Sloan EK, James PA, Campbell IG.
J Natl Cancer Inst. 2022 Oct 31:djac196. doi: 10.1093/jnci/djac196. Epub ahead of print.
PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical Oncology.
Miglietta F, Cinquini M, Dieci MV, Cortesi L, Criscitiello C, Montemurro F, Del Mastro L, Zambelli A, Biganzoli L, Levaggi A, Piane CD, Marchiò C, Calabrese M, Fortunato L, Franco P, Meduri B, Fittipaldo VA, Gori S.
Breast. 2022 Oct 29:S0960-9776(22)00179-5. doi: 10.1016/j.breast.2022.10.014. Epub ahead of print.
Evaluation of family history in individuals with heterozygous BRCA pathogenic variants diagnosed with breast or ovarian cancer in a single center in Italy.
Negri S, De Ponti E, Sina FP, Sala E, Dell'Oro C, Roversi G, Lazzarin S, Delle Marchette M, Inzoli A, Toso C, Fumagalli S, Campanella M, Kotsopoulos J, Fruscio R.
Mol Genet Genomic Med. 2022 Oct 28:e2071. doi: 10.1002/mgg3.2071. Epub ahead of print.
Platinum-based chemotherapy in locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC): summary of evidence and application in clinical practice.
Reinacher-Schick A, Arnold D, Venerito M, Goekkurt E, Kraeft AL, Seufferlein T.
Oncol Res Treat. 2022 Oct 28. doi: 10.1159/000527692. Epub ahead of print.